Toxicity, Disease Control, and Survival Outcomes of Intensified Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Single-Institution Study

References

• Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–iv40. doi:10.1093/annonc/mdx224
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu A, Sun X, et al. Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer. J Clin Oncol. 2020;38(36):4231–4239. doi:10.1200/JCO.20.01932
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, São Julião GP, et al. Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. Radiat Oncol. 2016;11(1). doi:10.1186/s13014-016-0598-6
   PubMedGoogle Scholar
• Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, Phase 2 trial. Lancet Oncol. 2015;16(8):957–966. doi:10.1016/S1470-2045(15)00004-2
   PubMed Web of Science ®Google Scholar
• Gérard J-P, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558–4565. doi:10.1200/JCO.2012.42.8771
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–2780. doi:10.1200/JCO.2010.34.4911
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107(11):djv248. doi:10.1093/jnci/djv248
   PubMedGoogle Scholar
• Rödel C, Graeven U, Fietkau R, et al; German Rectal Cancer StudyGroup. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (theGerman CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, Phase 3 trial. Lancet Oncol. 2015;16(8):979–989. doi:10.1016/S1470-2045(15)00159-X
   PubMed Web of Science ®Google Scholar
• O’Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol. 2016;34(27):3300–3307. doi:10.1200/JCO.2016.66.6198
   PubMedGoogle Scholar
• Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual [M]. 8th ed. New York: Springer; 2017.
   Google Scholar
• Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis. 2006;8(Suppl 3):21–24. doi:10.1111/j.1463-1318.2006.01066.x
   PubMedGoogle Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0[EB/OL].[2017-11-27][2019-8-15]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed April 27, 2023.
   Google Scholar
• Maas M, Beets⁃ Tan RG, Lambregts DM, et al. Wait- and- see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633. doi:10.1200/JCO.2011.37.7176
   PubMed Web of Science ®Google Scholar
• Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141⁃146. doi:10.1111/j.1365-2559.2005.02176.x
   PubMed Web of Science ®Google Scholar
• Tripathi P, Guo W, Rao S, Zeng M, Hu D. Additional value of MRI-detected EMVI scoring system in rectal cancer: applicability in predicting synchronous metastasis. Tumori. 2020;106(4):286–294. doi:10.1177/0300891620901745
   PubMed Web of Science ®Google Scholar
• Achilli P, Radtke TS, Lovely JK, et al. Preoperative predictive risk to cancer quality in robotic rectal cancer surgery. Eur J Surg Oncol. 2021;47(2):317–322. doi:10.1016/j.ejso.2020.08.019
   PubMed Web of Science ®Google Scholar
• Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-based Adjuvant Chemotherapy for Rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol. 2019;37(33):3111–3123. doi:10.1200/JCO.19.00016
   PubMed Web of Science ®Google Scholar
• Diefenhardt M, Ludmir EB, Hofheinz RD, et al. Association of treatment adherence with oncologic outcomes for patients with rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1416–1421. doi:10.1001/jamaoncol.2020.2394
   PubMed Web of Science ®Google Scholar
• Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: group cancer de recto 3 study. J Clin Oncol. 2010;28(5):859–865. doi:10.1200/JCO.2009.25.8541
   PubMed Web of Science ®Google Scholar
• Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37(34):3223–3233. doi:10.1200/JCO.18.02309
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase IIstudy. Radiat Oncol. 2014;9:70. doi:10.1186/1748-717X-9-70
   PubMed Web of Science ®Google Scholar
• Bregni G, Akin Telli T, Camera S, et al. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. Cancer Treat Rev. 2020;82:101930. doi:10.1016/j.ctrv.2019.101930
   PubMed Web of Science ®Google Scholar
• Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2021 Feb;22(2):e42]. Lancet Oncol. 2021;22(1):29–42. doi:10.1016/S1470-2045(20)30555-6
   PubMed Web of Science ®Google Scholar
• Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–715. doi:10.1016/S1470-2045(21)00079-6
   PubMed Web of Science ®Google Scholar
• Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681–1692. doi:10.1200/JCO.21.01667
   PubMed Web of Science ®Google Scholar
• Bujko K, Wyrwicz L, Rutkowski A, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834–842. doi:10.1093/annonc/mdw062
   PubMed Web of Science ®Google Scholar
• Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271(3):440–448. doi:10.1097/SLA.0000000000003471
   PubMed Web of Science ®Google Scholar
• Mahmoud NN. Colorectal cancer: preoperative evaluation and staging. Surg Oncol Clin N Am. 2022;31(2):127–141. doi:10.1016/j.soc.2021.12.001
   PubMed Web of Science ®Google Scholar
• Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. 2017;18(3):573. doi:10.3390/ijms18030573
   PubMed Web of Science ®Google Scholar
• Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34(27):3300–3307. doi:10.1200/JCO.2016.66.6198
   PubMed Web of Science ®Google Scholar
• Fokas E, Fietkau R, Hartmann A, et al. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. Ann Oncol. 2018;29(7):1521–1527. doi:10.1093/annonc/mdy143
   PubMed Web of Science ®Google Scholar
• Sipaviciute A, Sileika E, Burneckis A, Dulskas A. Late gastrointestinal toxicity after radiotherapy for rectal cancer: a systematic review. Int J Colorectal Dis. 2020;35(6):977–983. doi:10.1007/s00384-020-03595-x
   PubMed Web of Science ®Google Scholar
• Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212–3222. doi:10.1200/JCO.19.00308
   PubMedGoogle Scholar